psychedelics

Addressing Cannabis Hyperemesis Syndrome in Canada

Report

21 January 2026

Cannabis is one of the most commonly used substances in Canada. In 2024, about one in four people (26%) people living in Canada said they had used cannabis within the past year, and 6% said they used it daily or almost daily (Health Canada...

Intellectual Property of Psychedelics for Addiction Treatment: Enabling Access and Protecting Innovation Opportunities Through Preserving the Public Domain

Scientific article

3 October 2023

Recent studies highlight the potential of psychedelic-based treatments for addiction. However, certain academic institutions, companies, and individuals are attempting to monopolize these compounds by exploiting the patent system. This...

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Scientific article

5 June 2023

Abstract Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants...

NIH Workshop on Psychedelics as Therapeutics

12 January 2022

Washington, D.C.

United States

To learn what does Science can tell about the gaps, challenges, and opportunities on psychedelics as therapeutics, the US National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) will host a virtual and free workshop on January 12 and 13, 2022.

NIH Workshop on Psychedelics as Therapeutics: Gaps, Challenges and Opportunities

12 January 2022

Washington DC

United States

Register now: https://www.eventbrite.com/e/workshop-on-psychedelics-as-therapeutics-gaps-challenges-opportunities-tickets-216497739567?keep_tld=1

The NIH Workshop on Psychedelics as Therapeutics is sponsored by the National Institute of Mental H

Interdisciplinary Conference on Psychedelic Research

24 April 2020

Haarlem

Netherlands

The fourth edition of the Interdisciplinary Conference on Psychedelic Research. ICPR 2020 takes place from Friday 24 to Sunday 26 April 2020 in Haarlem, The Netherlands.

Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study

Scientific article

12 April 2017

ABSTRACT Background: The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability...